SCHEMBL3553261

SCHEMBL3553261

COC(=S)c1cc(OC)cc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADCY8 P40145 3/20 0.43
ADCY1 Q08828 3/20 0.43
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
NOTUM Q6P988 1/20 0.41
PTGS1 P23219 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 1/20 0.39
TMPRSS4 Q9NRS4 1/20 0.39
PHGDH O43175 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3551956 0.87 CES2 (0.48) HDAC3HDAC6NOTUMGAAMAPT
SCHEMBL3549813 0.84 RXRA (0.44) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL3548311 0.83 HDAC3 (0.42) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL628084 0.83 RXRA (0.43) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL16952326 0.80 PTGS1 (0.47) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL1189091 0.79 NOTUM (0.66) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL18380952 0.79 PTGS1 (0.46) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL1189514 0.77 RXRA (0.48) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL627645 0.77 RXRA (0.51) ADCY8ADCY1HDAC3HDAC1HDAC2
SCHEMBL31133384 0.77 RXRA (0.51) ADCY8ADCY1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE ADCY8 1481/4885ADCY1 2964/4885HDAC3 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.